A Phase 3 study of Ramantamig plus Daratumumab versus standard therapy in newly diagnosed multiple myeloma

Recruiting Phase 3 NCT07665450

Study Description

A study comparing a new combination treatment (ramantamig with daratumumab) against current standard treatments for people newly diagnosed with multiple myeloma who are not planned to receive a stem cell transplant

Study Details

Registry ID:
NCT07665450
Conditions:
Multiple Myeloma
Phase:
Phase 3
Target Enrollment:
1,000 participants
Start Date:
Age Range:
18–999 years
Healthy Volunteers:
No

Study Locations (30 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →